Purpose: In this open-label, randomized study, we assessed the effects on hemostasis of two combined oral contraceptives containing drospirenone (DRSP) as progestogen component. Methods: Three milligrams of DRSP, a progestogen with antimineralocorticoid activity, was combined with either 30 or 20 μg ethinyl estradiol (EE) (DRSP/30EE; DRSP/20EE) and compared with a preparation containing 150 μg desogestrel (DSG) and 30 μg ethinyl estradiol (DSG/30EE). A total of 75 healthy female volunteers aged 18-35 years were enrolled. The hemostasis variables were measured in the medication-free precycle (baseline); in the first, third and sixth treatment cycle; and in the follow-up phase. The target variables for comparison were the relative changes fro...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...
The aim of this study is to compare the effect of ethinyl estradiol 0.03 mg/gestodene 0.075 mg (EE/G...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...
Objective: To assess the effect on hemostasis parameters of a new combined oral contraceptive (COC)....
Objective: To assess the effect on hemostasis parameters of a new combined oral contraceptive (COC)....
Purpose: The aim of this study was to compare effects of the transdermal contraceptive patch, a deso...
OBJECTIVES: To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg...
Objectives To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg l...
OBJECTIVES: To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg...
Introduction: Oral contraceptives (OC) increase the risk of venous thromboembolism that depends on t...
Introduction: Oral contraceptives (OC) increase the risk of venous thromboembolism that depends on t...
Introduction: Oral contraceptives (OC) increase the risk of venous thromboembolism that depends on t...
Background: The objective of this study was to evaluate the effects of a contraceptive pill containi...
Background: The objective of this study was to evaluate the effects of a contraceptive pill containi...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...
The aim of this study is to compare the effect of ethinyl estradiol 0.03 mg/gestodene 0.075 mg (EE/G...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...
Objective: To assess the effect on hemostasis parameters of a new combined oral contraceptive (COC)....
Objective: To assess the effect on hemostasis parameters of a new combined oral contraceptive (COC)....
Purpose: The aim of this study was to compare effects of the transdermal contraceptive patch, a deso...
OBJECTIVES: To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg...
Objectives To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg l...
OBJECTIVES: To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg...
Introduction: Oral contraceptives (OC) increase the risk of venous thromboembolism that depends on t...
Introduction: Oral contraceptives (OC) increase the risk of venous thromboembolism that depends on t...
Introduction: Oral contraceptives (OC) increase the risk of venous thromboembolism that depends on t...
Background: The objective of this study was to evaluate the effects of a contraceptive pill containi...
Background: The objective of this study was to evaluate the effects of a contraceptive pill containi...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...
The aim of this study is to compare the effect of ethinyl estradiol 0.03 mg/gestodene 0.075 mg (EE/G...
Background: Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, p...